

December 3, 2018

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Mothers)

Inquiries: Arihiko Bijohira, Executive Director & CFO

Phone: +81-3-6383-3746

[Summary] Asset Purchase Agreement of Tb535H and Trisoma® technology

Chiome Bioscience Inc. (hereinafter, "Chiome"), an antibody drug discovery and development company, is pleased to announce that it has executed an Asset Purchase Agreement with Biotecnol Limited (Home office: London, United Kingdom; hereinafter, "BT").

Under this agreement, BT will transfer its immuno-oncology pipeline and respective technologies (including Tb535H and Trisoma®) to Chiome. Chiome is planning to advance research and development activities of Tb535H for future clinical development and out-licensing. In addition, we will engage in generating new pipeline using the Trisoma® technology.

Impact on the financial performance for the fiscal period ending December 31, 2018 is unknown. Chiome will make an announcement if its impact becomes clear.

<About Tb535H>

Tb535H is a T-cell engager, trispecific antibody, directed against the 5T4/WAIF1 tumour antigen, a protein found on many different solid tumours and is thought to contribute to the spread of cancer cells. Tb535H recruits the patient's T-cells –killer cells of the immune-system – and directs them to attack tumours. This highly targeted approach uses the patient's own immune system to fight cancer. The WAIF1 antigen was discovered by scientists at the Cancer Research UK Manchester Institute. It could be a valuable target in many different cancer types, but the initial focus in this trial will be to treat cancers with high unmet-need. This includes thoracic cancers such as mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), for which survival remains very low, and renal cell carcinoma.

<About Trisoma® technology>

The Trisoma® technology enables the generation of multi-specific antibody products. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats. With the Trisoma® technology, Biotecnol can engineer and assemble recombinant antibodies in a rational manner in order to design a chosen mechanism of action to address the killing of a specific tumour type.

<About Biotecnol Limited>

Biotecnol Limited is a London (UK) based immuno-oncology company developing innovative immune-function activating and immune-function modulation approaches for treating cancer. These approaches seek to recruit or to modulate the body's own immune defences such as T cells and NK cells to kill tumours. Biotecnol multi-specific antibody products are based on its proprietary Trisoma® platform, which are comprised of a variety of formats with key properties. Under the Trisoma®

platform, Bioteclol has developed a novel format known as Targeted T-cell Engaging Agonistic Response Modifiers or iChecks. These products aim at improving tumour cell dependent T-cell or NK-cell activation. The iCheck formats are expected to achieve a more localized immune-function activation and obtain less or no systemic toxicity, whilst having an increased therapeutic index. These are potentially safer and more effective drugs for treating highly-heterogeneous and highly-aggressive solid tumours. (<http://www.bioteclol.com/>)